| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1985 | |
| Phytochemical name or plant extracts | 2,3,5,4'-Tetrahydroxystilbene-2-O-β-d-glucoside (THSG) | |
| PMID | 30555223 | |
| Literature evidence | OBJECTIVE: Breast cancer has been reported to be a serious disease and a threat to women's health. 2,3,5,4'-Tetrahydroxystilbene-2-O-β-d-glucoside (THSG) is a bioactive natural compound originating from Polygonum multiflorum Thunb., which has been shown to possess anti-inflammatory and antitumor properties. | |
| IUPAC name | (2R,3S,4R,5R)-2-[2,4-dihydroxy-6-[(E)-2-(4-hydroxyphenyl)ethenyl]phenoxy]-3,4,5,6-tetrahydroxyhexanal | |
| Phytochemicals’ class or type of plant extracts | Stilbenoid | |
| Source of phytochemicals or plant Extracts | Polygonum multiflorum Thunb. | |
| Geographical availability | China North-Central, China South-Central, China Southeast, Hainan, Taiwan, Thailand, Vietnam | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | Bax, Bcl-2, Caspase 3 | |
| Gene or Protein evidence | The individual treatment of THSG and Adriamycin (ADM) induced cell injury. Moreover, cotreatment further increased it, which the effect may be associated with the elevation of the apoptotic-related protein expression such as Bax/Bcl-2 and cleaved caspase-3/caspase-3. | |
| Target pathways | vascular endothelial growth factor/phosphatidylinositol 3-kinase/Akt pathway | |
| IC50 | THSG and ADM decreased cell viability, with a higher IC50 value (359.6 µM) for THSG and a lower IC50 value (0.78 µM) for ADM in MCF-7 cells at 48 hours. The drug combination of THSG and ADM was administered at 400:1 (THSG:ADM) fixed molar ratio for 48 hours and showed an IC50 value of 164.6 + 0.41 µM. | |
| Potency | Thus, THSG might possess potent anti-breast cancer effect with ADM. | |
| Cell line/ mice model | MCF-7, H1299 and LNC | |
| Additional information | Importantly, THSG is water soluble and exerts almost no cardiac toxicity. Accordingly, THSG, as an adjuvant agent, served as a drug that can regulate the VEGF/PI3K/Akt pathway for treating breast cancer, which could minimize the adverse effects of ADM, improve clinical outcomes, and contribute to elevating the quality of life of patients. | |
| PubChem ID | 6438627 | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:927345-1 | |
| Safety | NA |